30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

A Final Look at 2010 Results: Anika Therapeutics

ANIKA THERAPEUTICS
Orthobiologics $30.7MM, +34% (ORTHOVISC U.S. +32%, ex-U.S. -8%; MONOVISC in EU +126%)

4Q10 revenue: $8.4MM, +40% (U.S. +25%, ex-U.S. +96%; ORTHOVISC U.S. +25%, ex-U.S. +21%)
* Requested review of MONOVISC via FDA’s orthopaedic advisory panel, no meeting date
set yet